Intradermal injections made easy

Traditional injection methods are awkward to use and often lead to misinjections. The time has come for an innovative microinjection system that delivers the right dose in the right place.

	The microneedle is applied perpendicularly to the skin to ensure that fluid is delivered directly in the intradermal space.

The Mantoux technique for intradermal injection is difficult to master and prone to mis-injections. The BD Soluvia™ Microinjectionsystem has been developed to considerably simplify and improve the success rate of intradermal injections.

Intuitive use
In tests, clinicians achieved a high injection success rate whether or not they were previously trained (Figure 1). In fact, clinicians who had no prior training and received
the deliberately misleading instructions for use (IFU) had a success rate equivalent to
those who were trained and had the correct IFU.

Since nearly every practitioner regardless of training experience can reliably create successful intradermal injections, the BD Soluvia Microinjection system can greatly facilitate the widespread use of intradermal injection.

Universal use
BD Soluvia is designed to provide reliable and consistent delivery into the dermal layer of the skin regardless of subject’s profile. For example, it is equally effective in people of various ages, BMI and gender. Interestingly, at the four major sites of
injection (thigh, waist, deltoid and suprascapular), no significant difference in
the thickness of the dermis exists between subjects of Caucasian, African or Asian
origin (Figure 2).



Simply innovative
BD Soluvia is pre-filled and ready to use, eliminating the preparation time required
with the conventional vials and tuberculin syringe. Also, since the needle is already affixed to the syringe, there is no need for luer transfer needles. Before use, no purging of the syringe is required. After use, the needle protection shield that is activated by the user provides for built-in needlestick prevention.

Another advantage is its short, thin and minimally invasive microneedle. A 30 gauge is significantly smaller (around 50% less in diameter) than the 26 gauge used for Mantoux injections. Moreover, the shallow depth of the injection (1.5mm) and
the small injected volume (typically 100uL) make the BD Soluvia microinjection system minimally invasive.

All these factors may contribute to the near imperceptible perception of the microneedle by patients. By providing an innovative, easy-to-use, intuitive and reliable means of delivering therapeutics to the intradermal space, BD Soluvia is expected to revive the use of this route of administration and possibly expand the
use of some drugs.

The first commercial launch of a product using BD Soluvia Microinjection system is expected at the end of 2009.

Company profile

BD, a leading global medical technology company that manufactures and sells medical devices, instrument systems and reagents, is dedicated to improving people’s health throughout the world. BD focuses on improving drug therapy, enhancing the quality and speed of diagnosing infectious diseases and cancers, and advancing research and discovery of new drugs and vaccines.

For more information, contact anne-marie.branchard@europe. bd.com or visit www.bd.com.

The microneedle is applied perpendicularly to the skin to
ensure that fluid is delivered directly in the intradermal space.